目的观察阿奇霉素联合蒙脱石散治疗肺炎支原体肺炎的临床疗效。方法将156例肺炎支原体肺炎患儿按治疗方法的不同分为2组:观察组(联合用药组,80例)和对照组(红霉素组,76例)。2组患儿均采用一般治疗(保持室内空气新鲜、保持气道通畅,经常给患儿翻身、拍背,促进分泌物排出,必要时可适当吸痰,对有低氧表现的给予吸氧)和退热、止咳、化痰及平喘等对症处理。在此基础上,对照组采用红霉素治疗,观察组采用阿奇霉素联合蒙脱石散治疗。观察2组患儿临床疗效及不良反应的情况。结果观察组总有效率明显高于对照组(88.8%比76.3%,P<0.05),观察组不良反应发生率明显低于对照组(5.0%比27.6%,P<0.01)。结论阿奇霉素联合蒙脱石散治疗小儿支原体肺炎较单纯应用红霉素治疗显效快,并可减轻全身不良反应,是治疗小儿支原体肺炎的良好药物。 Objective To observe the clinical efficacy of azithromycin combined with montmorillonite powder in the treatment of Mycoplasma pneumoniae pneumonia. Methods 156 cases of children with Mycoplasma pneumoniae pneumonia were divided into two groups according to different treatment methods: observation group (combination group, 80 cases) and control group (erythromycin group, 76 cases). 2 groups of children were treated with general (to keep the indoor fresh air, keep the airway open, often to children stand up, beat back, promote secretions discharge, if necessary, appropriate suction, hypoxic performance to give oxygen) And fever, cough, phlegm and asthma symptomatic treatment. On this basis, the control group with erythromycin treatment, the observation group with azithromycin montmorillonite treatment. The clinical efficacy and adverse reactions of the two groups were observed. Results The total effective rate in the observation group was significantly higher than that in the control group (88.8% vs 76.3%, P <0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (5.0% vs 27.6%, P <0.01). Conclusion Azithromycin plus montmorillonite powder treatment of children with mycoplasma pneumonia than erythromycin alone treatment markedly effective, and reduce systemic adverse reactions, is a good drug for the treatment of children with mycoplasma pneumonia.